vincentcouey/brand-to-generic-patent-cliff-2026

RxGrab 2026 Brand-to-Generic Patent Cliff Audit Aggregated cost-drop, time-to-generic, and stalled-generic audit covering 50 high-volume US prescription drugs across 24 therapeutic categories. License: CC-BY 4.0 DOI: 10.5281/zenodo.20632747 Source study: https://rxgrab.com/research/brand-to-generic-patent-cliff-2026/ Author: Vincent Wesley Couey (ORCID 0009-0005-6869-308X) · published via RxGrab (rxgrab.com), part of the Lattice research network. What's in it… See the full description on the dataset page: https://huggingface.co/datasets/vincentcouey/brand-to-generic-patent-cliff-2026.